How do we meet the challenge of chimeric antigen receptor T-cell therapy for solid tumors? Review

   


Authors: Schoenfeld, A. J.; O'Cearbhaill, R. E.
Review Title: How do we meet the challenge of chimeric antigen receptor T-cell therapy for solid tumors?
Abstract: ABSTRACT: Immune checkpoint inhibition has vastly improved the treatment of solid tumors, but most patients do not experience durable clinical benefit, so novel immunotherapeutic approaches are needed. Autologous T cells genetically engineered to express chimeric antigen receptors (CARs) have led to unprecedented clinical success in hematologic malignancies, and increasing efforts are actively being pursued to translate these benefits to the solid tumor arena. However, solid tumors present unique challenges for CAR T-cell development. In this review, we examine the potential barriers to progress and present emerging approaches to overcome these challenges with CAR therapy in solid tumors. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Journal Title: The Cancer Journal
Volume: 27
Issue: 2
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2021-03-01
Start Page: 134
End Page: 142
Language: English
DOI: 10.1097/ppo.0000000000000516
PUBMED: 33750073
PROVIDER: scopus
PMCID: PMC8457037
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103474069&doi=10.1097%2fPPO.0000000000000516&partnerID=40&md5=f3b6c1576cbeba8419cdfc763697dd9f
Notes: Article -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Roisin Eilish O'Cearbhaill
    272 O'Cearbhaill
  2. Adam Jacob Schoenfeld
    132 Schoenfeld
Related MSK Work